Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer:Real world experience in Greater Manchester, UK

Autor: J. Loncaster, Gregory C. Wilson, Sacha J Howell, Richard Welch, Abbas Chittalia, Anne C Armstrong, W Valentine, Nigel J Bundred

Publikováno v: Loncaster, J, Armstrong, A, Howell, S, Wilson, G, Welch, R, Chittalia, A, Valentine, W J & Bundred, N J 2017, ' Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer : Real world experience in Greater Manchester, UK ', European Journal of Surgical Oncology, vol. 43, no. 5, pp. 931-937 . https://doi.org/10.1016/j.ejso.2016.12.010

Background The National Institute for Health and Clinical Excellence (NICE) recommended the Oncotype DX® Breast Recurrence Score® (RS) assay as an option for informing adjuvant chemotherapy decisions in node-negative, oestrogen receptor (ER)+, huma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd2e4eadc3dc2c3c4a05685acba4ab2a
https://research.manchester.ac.uk/en/publications/7aeece5e-8209-44bd-990e-c42baee582fd

Eribulin for advanced breast cancer: Clinical experience in the real world

Autor: Brian Magee, Richard C. Walshaw, Christine Tetlow, Lubna Bhatt, Andrew M Wardley, Shazril Shaukat, Juliet Loncaster, Anne C Armstrong, Abbas Chittalia, Sacha J Howell, Vivek Misra, Gregory C. Wilson, Kevin Chan, Helen Lander

Publikováno v: ResearcherID

e12003 Background: A number of cytotoxic agents are used for the treatment of advanced breast cancer. Benefit beyond 2 lines of palliative chemotherapy remains poor. Eribulin is a new IV cytotoxic ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b402ecbc5b57897ff681ced3bbfff8e7
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000358613200098&KeyUID=WOS:000358613200098